Galapagos Price to Book Ratio 2013-2021 | GLPG

Historical price to book ratio values for Galapagos (GLPG) over the last 10 years. The current price to book ratio for Galapagos as of October 15, 2021 is 1.09.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Galapagos Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-15 53.52 1.09
2021-06-30 68.89 $48.98 1.41
2021-03-31 77.09 $49.71 1.55
2020-12-31 98.98 $46.63 2.12
2020-09-30 141.91 $48.52 2.92
2020-06-30 197.29 $46.80 4.22
2020-03-31 195.92 $48.34 4.05
2019-12-31 206.83 $49.81 4.15
2019-09-30 152.66 $45.51 3.35
2019-06-30 128.93 $23.44 5.50
2019-03-31 117.78 $24.45 4.82
2018-12-31 91.74 $26.33 3.48
2018-09-30 112.43 $25.44 4.42
2018-06-30 92.18 $20.57 4.48
2018-03-31 99.76 $21.58 4.62
2017-03-31 86.19 $17.90 4.82
2016-03-31 41.82 $17.53 2.39
2015-12-31 62.88 0.00
2015-09-30 40.71 0.00
2015-06-30 51.50 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.507B $0.606B
Galapagos NV is a biotechnology company. The Company's operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00